Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
W. L. Gore & Associates acquisition of Conformal Medical
We are advising Gore on the transaction
InSilico Medicine HK$2.62 billion IPO
We advised InSilico Medicine on its IPO and HKEX listing
PegBio HK$300 million placement of shares
We advised PegBio on the placement of new shares
GSK strategic collaboration with CAMP4 Therapeutics
We advised GSK on the transaction
Kodiak Sciences $184 million stock offering
We advised the underwriters on the offering
Zoetis $2 billion convertible senior notes offering
We advised the representatives of the initial purchasers on the offering
Tenaya Therapeutics $60 million units offering
We advised the joint book-running managers and representatives of the several underwriters
LifeScan emerges from chapter 11
We advised an ad hoc group of secured lenders in connection with LifeScan’s chapter 11 proceedings
Sevita $1.275 billion notes offering
We advised the representative of the initial purchasers on the offering
Terns Pharmaceuticals $747.5 million stock offering
We advised the underwriters on the public offering